-
Product Insights
Essar Oil/ Fulcrum BioEnergy/ Stanlow Terminals – Fulcrum NorthPoint SAF Refinery – Cheshire West and Chester
Equip yourself with the essential tools needed to make informed and profitable decisions with our Essar Oil/ Fulcrum BioEnergy/ Stanlow Terminals - Fulcrum NorthPoint SAF Refinery - Cheshire West and Chester report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report?...
-
Product Insights
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha Synuclein (SNCA) Drugs in Development Report Overview Alpha-synuclein is a protein normally found in cells all over the body and is one of the key players in Parkinson’s disease. The Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) drugs in development research report provides comprehensive information on the therapeutics under development for Alpha Synuclein. The report also analyzes the stage of development, mechanism of action (MoA), route...
-
Product Insights
Net Present Value Model: FTX-6058
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model FTX-6058 Drug Details Small molecule is...
-
Product Insights
Net Present Value Model: Losmapimod
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Losmapimod Drug Details Losmapimod (GW-856553X) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FTX-6058
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FTX-6058 Drug Details Small molecule is under development for the treatment of sickle cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – losmapimod
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry losmapimod Drug Details Losmapimod (GW-856553X) is under development for the treatment of facioscapulohumeral muscular...
-
Product Insights
Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Muscular Dystrophy Pipeline Drugs Market Report Overview Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The report titled ‘Muscular Dystrophy –Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update’, provides an overview of...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Sickle Cell Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain, and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion, and stem cell transplant. The Sickle Cell Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
Friedreich Ataxia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Friedreich Ataxia Drugs in Development Report Overview Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Its signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis...